NBSE - NeuBase Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.08
+0.15 (+3.04%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close4.93
Open4.94
Bid0.00 x 3200
Ask0.00 x 1300
Day's Range4.94 - 5.24
52 Week Range3.36 - 6.95
Volume44,476
Avg. Volume67,436
Market Cap84.637M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.12
Earnings DateJan 1, 2020 - Jan 6, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.50
  • GlobeNewswire

    NeuBase Therapeutics to Present at the Stifel 2019 Healthcare Conference

    PITTSBURGH, Nov. 12, 2019 -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to.

  • GlobeNewswire

    NeuBase Therapeutics Announces Issuance of Foundational Patent Covering the Key Building Blocks of PATrOL™ Enabled Therapies

    NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,370,415 covering the Company’s proprietary DNA and RNA binding technology. This foundational patent enables PATrOL™-based therapies to target the secondary structures of DNA and RNA. “The technology in this patent covers bi-specific nucleobases, which uniquely enables NeuBase to bind and manipulate the hard-to-reach double helix of the human genome and secondary structures of RNA,” said Dietrich Stephan, Ph.D., chief executive officer of NeuBase Therapeutics.

  • GlobeNewswire

    NeuBase Therapeutics Announces Appointment of Cancer Biologist and RNA Therapeutics Specialist Steven Dowdy, Ph.D., to Scientific Advisory Board

    NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced the addition of Steven Dowdy, Ph.D., to its scientific advisory board (SAB). Dr. Dowdy joins preeminent scientists George Church, Ph.D., and Samuel Broder, M.D., on the NeuBase SAB. “Dr. Dowdy’s considerable expertise in RNA therapeutics perfectly complements the expertise of our current SAB as well as the direction of our company, and we are fortunate to have him as an advisor as we advance our PATrOL™-enabled therapies,” said Dietrich Stephan, Ph.D., chief executive officer of NeuBase.

  • GlobeNewswire

    NeuBase Therapeutics to Present at the Chardan 3rd Annual Genetic Medicines Conference

    PITTSBURGH, Sept. 26, 2019 -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to.

  • ACCESSWIRE

    Micro-Cap Rodeo Investor Conference October in Austin Texas

    Company lineup is filling up fast with 50 good names in the microcap markets, as well as some great private and Pre-IPO companies AUSTIN, TX / ACCESSWIRE / September 19, 2019 / The MicroCap Rodeo's inaugural ...

  • GlobeNewswire

    NeuBase Therapeutics Hosting Key Opinion Leader Meeting on Huntington's Disease and PATrOL™-Enabled Therapy on September 16th

    NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced that it will host a Key Opinion Leader (KOL) meeting on Huntington's disease and NeuBase’s peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform on Monday, September 16, 2019 in New York City. The meeting will feature presentations by KOL George Church, PhD, professor of genetics at Harvard Medical School, and Robert Friedlander, MD, chairman of the Department of Neurological Surgeons University of Pittsburgh Medical Center and the University of Pittsburgh Medical School, who will discuss Huntington's disease, the current treatment landscape and the genomic revolution culminating in the NeuBase technology platform.

  • GlobeNewswire

    NeuBase Therapeutics Reports Financial Results for the Fiscal Third Quarter of 2019

    Completed two financings in July 2019 totaling approximately $14 million in gross proceeds with participation from institutional investors including Greenlight Capital.

  • GlobeNewswire

    NeuBase Therapeutics to Ring the NASDAQ Closing Bell Today

    NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” and the “Company”), a biotechnology company developing next generation antisense therapies to address genetic diseases, announced today that its chairman and chief executive officer, Dietrich A. Stephan, Ph.D., will be joined by other members of the management team to ring the NASDAQ closing bell today, August 7, 2019, to celebrate the Company’s recent listing on the NASDAQ. “The NeuBase management team and the board of directors are honored to celebrate the Company’s recent listing on the NASDAQ by ringing the NASDAQ closing bell later today,” said Dr. Stephan.

  • GlobeNewswire

    NeuBase Therapeutics Announces Addition of Industry Pioneer Dr. Samuel Broder and World-Renowned Geneticist Dr. George Church to Scientific Advisory Board

    NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced the addition of Samuel Broder, M.D, Ph.D. and George Church, Ph.D. to its scientific advisory board (SAB), bringing additional expertise in genetics, genomics, and oncology to a team already recognized for leadership in neurology, genomics and therapeutic development. The SAB will work closely with the NeuBase management team as the Company advances its next-generation gene regulating therapies through development, first in genetic diseases such as the repeat expansion disorders Huntington’s disease and myotonic dystrophy, as well as oncology, and then more broadly.

  • GlobeNewswire

    NeuBase Therapeutics Appoints Danith Ly, Ph.D. as Chief Scientific Officer

    NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced the appointment of Danith Ly, Ph.D., as chief scientific officer. Dr. Ly is the primary inventor of NeuBase’s peptide nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform technology, which the Company is leveraging to develop a pipeline of gene modifying therapies. Dr. Ly joins NeuBase as the Company is advancing its first PATrOL-enabled therapies through preclinical development and expanding its pipeline across rare genetic diseases as well as additional genetically-driven disorders.

  • GlobeNewswire

    NeuBase Therapeutics Initiates Trading on NASDAQ Under Ticker Symbol “NBSE”

    NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” and the “Company”), a biotechnology company developing next generation antisense therapies to address genetic diseases, announced today that its common stock began trading on The Nasdaq Capital Market under the ticker symbol “NBSE” at the open of market trading today, July 15, 2019, and will cease using the previous ticker symbol, “OHRP”. On Friday, July 12th, the Company announced the completion of the merger between NeuBase Therapeutics, Inc. and Ohr Pharmaceutical, Inc. (“Ohr”) and associated financings. Immediately upon completion of the merger, the combined company changed its name to “NeuBase Therapeutics, Inc.”.